• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

Filters [Clear]
  • Price Sensitive: Yes
SUD Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
SUD Appendix 4C AmendedPRICE SENSITIVE04/02/19
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
SUD SUDA Signs Agreement With Mitsubishi TanabePRICE SENSITIVE19/12/18
SUD ZLD: ZLD to Invest in Development of Oral Spray FormulationsPRICE SENSITIVE06/12/18
SUD SUDA Enters Agreement To Develop Cannabinoid SprayPRICE SENSITIVE06/12/18
SUD SUDA Receives R&D Tax Incentive RefundPRICE SENSITIVE15/11/18
SUD ZolpiMist Market UpdatePRICE SENSITIVE13/11/18
SUD SUDA Signs Agreement For SUD-001H For US MarketPRICE SENSITIVE08/11/18
SUD Trading HaltPRICE SENSITIVE07/11/18
SUD Appendix 4C, Market Update and Top 20PRICE SENSITIVE29/10/18
SUD Reinstatement to Official QuotationPRICE SENSITIVE17/10/18
SUD Response to ASX Price QueryPRICE SENSITIVE17/10/18
SUD Suspension from Official QuotationPRICE SENSITIVE17/10/18
SUD Pause in TradingPRICE SENSITIVE17/10/18
SUD Market UpdatePRICE SENSITIVE12/09/18
SUD Request for Trading HaltPRICE SENSITIVE11/09/18
SUD Trading HaltPRICE SENSITIVE11/09/18
SUD Pause in TradingPRICE SENSITIVE11/09/18
SUD Preliminary Final ReportPRICE SENSITIVE31/08/18
SUD SUDA Achieves TGA GMP LicencePRICE SENSITIVE21/08/18
SUD Rights Issue Closes Significantly OversubscribedPRICE SENSITIVE31/07/18
SUD Supplementary ProspectusPRICE SENSITIVE31/07/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
SUD Business Development UpdatePRICE SENSITIVE16/07/18 download Created with Sketch. 147.27KB
SUD Anagrelide UpdatePRICE SENSITIVE12/07/18 download Created with Sketch. 648.78KB
SUD Prospectus for a Renounceable Pro Rata OfferPRICE SENSITIVE02/07/18 download Created with Sketch. 1.34MB
SUD Settlement with HC Berlin Pharma and Rights IssuePRICE SENSITIVE02/07/18 download Created with Sketch. 196.79KB
SUD Trading HaltPRICE SENSITIVE28/06/18 download Created with Sketch. 149.12KB
SUD Shareholder UpdatePRICE SENSITIVE21/06/18 download Created with Sketch. 169.11KB
SUD SUDA Expands Patent Coverage For SildenafilPRICE SENSITIVE18/06/18 download Created with Sketch. 141.45KB
SUD SUDA announces update on ZolpiMist in USA and CanadaPRICE SENSITIVE15/06/18 download Created with Sketch. 646.48KB
SUD SUDA expands dialogue with World Health OrganisationPRICE SENSITIVE07/05/18
SUD HC Berlin Pharma UpdatePRICE SENSITIVE01/05/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
SUD HC Berlin Pharma UpdatePRICE SENSITIVE29/03/18
SUD SUDA Completes Divestment of SubsidiaryPRICE SENSITIVE08/03/18
SUD Half Yearly Report and AccountsPRICE SENSITIVE28/02/18
SUD Divestment Of Non-Core SubsidiaryPRICE SENSITIVE27/02/18
SUD New Analyst ReportPRICE SENSITIVE16/02/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
SUD SUDA Completes Acquisition Of Anti-Cancer AgentPRICE SENSITIVE24/01/18
SUD SUDA's Licensee Submits Marketing ApplicationPRICE SENSITIVE06/12/17
SUD SUDA Receives R&D Tax Incentive RefundPRICE SENSITIVE30/11/17
SUD SUDA Acquires Novel Oro-Mucosal Anti-Cancer AgentPRICE SENSITIVE28/11/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
SUD SUDA Publishes Amended Shareholder NewsletterPRICE SENSITIVE12/09/17
SUD Preliminary Final ReportPRICE SENSITIVE31/08/17
SUD SUDA Achieves ISO AccreditationPRICE SENSITIVE31/07/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE27/07/17
SUD Strong Revenue Growth for SUDA SubsidiaryPRICE SENSITIVE24/07/17
SUD SUDA Enters Licence Agreement With TevaPRICE SENSITIVE05/07/17
SUD Trading HaltPRICE SENSITIVE04/07/17
SUD SUDA Signs Term Sheet To Acquire Anti-Cancer AgentPRICE SENSITIVE20/06/17
SUD SUDA Meeting For Zolpimist Into EuropePRICE SENSITIVE25/05/17
SUD Placement, Interest Shares and Convertible Note ProspectusPRICE SENSITIVE24/04/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE19/04/17
SUD SUDA Completes $1.5m Capital RaisingPRICE SENSITIVE07/04/17
SUD Trading HaltPRICE SENSITIVE05/04/17
SUD SUDA Submits Application For ArTiMistPRICE SENSITIVE03/04/17
SUD SUDA Extends Maturity of Convertible NotesPRICE SENSITIVE03/04/17
SUD SUDA Enters Feasibility Agreement With PfizerPRICE SENSITIVE29/03/17
SUD SUDA expands patent coverage for SUD-003 and SUD-004PRICE SENSITIVE03/03/17
SUD SUDA Announces Strong Revenue For WestcoastPRICE SENSITIVE27/02/17
SUD Half Yearly Report and AccountsPRICE SENSITIVE27/02/17
SUD Reinstatement to official quotationPRICE SENSITIVE27/02/17
SUD SUDA Update On Discussions with Berlin PharmaPRICE SENSITIVE27/02/17
SUD Suspension from official quotationPRICE SENSITIVE27/01/17
SUD Trading HaltPRICE SENSITIVE24/01/17
SUD SUDA presents data on novel technologyPRICE SENSITIVE17/11/16
SUD SUDA Enters Licensing Agreement For ZolpiMist in ChinaPRICE SENSITIVE09/11/16
SUD Technology patent application-SUD.AX PRICE SENSITIVE02/11/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE31/10/16
SUD Preliminary Final Report-SUD.AX PRICE SENSITIVE31/08/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE29/07/16
SUD Update on HC Berlin Pharma-SUD.AX PRICE SENSITIVE03/06/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE29/04/16
SUD Business development update-SUD.AX PRICE SENSITIVE19/04/16
SUD SUDA granted Canadian Patent for SUD-002-SUD.AX PRICE SENSITIVE12/04/16
SUD Half Yearly Report and Accounts (including Appendix 4D)PRICE SENSITIVE26/02/16
SUD SUDA receives $0.7m R&D tax incentive refundPRICE SENSITIVE05/02/16
SUD Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
SUD SUDA amends agreement with Amherst PharmaceuticalsPRICE SENSITIVE10/12/15
SUD Response to Price Query LetterPRICE SENSITIVE07/12/15
SUD Appendix 4C - quarterlyPRICE SENSITIVE30/10/15
SUD SUDA allowed first USA patent for SUD-003 and SUD-004PRICE SENSITIVE08/10/15
SUD Preliminary Final ReportPRICE SENSITIVE31/08/15
SUD SUDA announces ArTiMist clinical publicationPRICE SENSITIVE27/08/15
SUD SUDA takes full control of ArTiMistPRICE SENSITIVE26/08/15
SUD SUDA receives positive response from FDA regarding SUD-001PRICE SENSITIVE06/08/15
SUD SUDA granted African patent for ArTiMistPRICE SENSITIVE31/07/15
SUD Appendix 4C - quarterlyPRICE SENSITIVE28/07/15
SUD SUDA granted US patent for SUD-002 oral sprayPRICE SENSITIVE27/07/15
SUD SUDA progresses business development at BIO 2015PRICE SENSITIVE29/06/15
SUD Appendix 4C - quarterlyPRICE SENSITIVE30/04/15
SUD SUDA announces ArTiMist peer-reviewed publicationsPRICE SENSITIVE24/04/15
SUD Suda completes $5.3m capital raisingPRICE SENSITIVE27/03/15
SUD Trading HaltPRICE SENSITIVE26/03/15
SUD Appendix 4D Half Year Ended 31 December 2014PRICE SENSITIVE27/02/15
SUD Suda Granted First Patent For Sildenafil In AustraliaPRICE SENSITIVE30/01/15
SUD Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
SUD Appendix 4C Amended
04/02/19PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
SUD SUDA Signs Agreement With Mitsubishi Tanabe
19/12/18PRICE SENSITIVE
SUD ZLD: ZLD to Invest in Development of Oral Spray Formulations
06/12/18PRICE SENSITIVE
SUD SUDA Enters Agreement To Develop Cannabinoid Spray
06/12/18PRICE SENSITIVE
SUD SUDA Receives R&D Tax Incentive Refund
15/11/18PRICE SENSITIVE
SUD ZolpiMist Market Update
13/11/18PRICE SENSITIVE
SUD SUDA Signs Agreement For SUD-001H For US Market
08/11/18PRICE SENSITIVE
SUD Trading Halt
07/11/18PRICE SENSITIVE
SUD Appendix 4C, Market Update and Top 20
29/10/18PRICE SENSITIVE
SUD Reinstatement to Official Quotation
17/10/18PRICE SENSITIVE
SUD Response to ASX Price Query
17/10/18PRICE SENSITIVE
SUD Suspension from Official Quotation
17/10/18PRICE SENSITIVE
SUD Pause in Trading
17/10/18PRICE SENSITIVE
SUD Market Update
12/09/18PRICE SENSITIVE
SUD Request for Trading Halt
11/09/18PRICE SENSITIVE
SUD Trading Halt
11/09/18PRICE SENSITIVE
SUD Pause in Trading
11/09/18PRICE SENSITIVE
SUD Preliminary Final Report
31/08/18PRICE SENSITIVE
SUD SUDA Achieves TGA GMP Licence
21/08/18PRICE SENSITIVE
SUD Rights Issue Closes Significantly Oversubscribed
31/07/18PRICE SENSITIVE
SUD Supplementary Prospectus
31/07/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
SUD Business Development Update
16/07/18PRICE SENSITIVE download Created with Sketch. 147.27KB
SUD Anagrelide Update
12/07/18PRICE SENSITIVE download Created with Sketch. 648.78KB
SUD Prospectus for a Renounceable Pro Rata Offer
02/07/18PRICE SENSITIVE download Created with Sketch. 1.34MB
SUD Settlement with HC Berlin Pharma and Rights Issue
02/07/18PRICE SENSITIVE download Created with Sketch. 196.79KB
SUD Trading Halt
28/06/18PRICE SENSITIVE download Created with Sketch. 149.12KB
SUD Shareholder Update
21/06/18PRICE SENSITIVE download Created with Sketch. 169.11KB
SUD SUDA Expands Patent Coverage For Sildenafil
18/06/18PRICE SENSITIVE download Created with Sketch. 141.45KB
SUD SUDA announces update on ZolpiMist in USA and Canada
15/06/18PRICE SENSITIVE download Created with Sketch. 646.48KB
SUD SUDA expands dialogue with World Health Organisation
07/05/18PRICE SENSITIVE
SUD HC Berlin Pharma Update
01/05/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
SUD HC Berlin Pharma Update
29/03/18PRICE SENSITIVE
SUD SUDA Completes Divestment of Subsidiary
08/03/18PRICE SENSITIVE
SUD Half Yearly Report and Accounts
28/02/18PRICE SENSITIVE
SUD Divestment Of Non-Core Subsidiary
27/02/18PRICE SENSITIVE
SUD New Analyst Report
16/02/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
SUD SUDA Completes Acquisition Of Anti-Cancer Agent
24/01/18PRICE SENSITIVE
SUD SUDA's Licensee Submits Marketing Application
06/12/17PRICE SENSITIVE
SUD SUDA Receives R&D Tax Incentive Refund
30/11/17PRICE SENSITIVE
SUD SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
28/11/17PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
SUD SUDA Publishes Amended Shareholder Newsletter
12/09/17PRICE SENSITIVE
SUD Preliminary Final Report
31/08/17PRICE SENSITIVE
SUD SUDA Achieves ISO Accreditation
31/07/17PRICE SENSITIVE
SUD Appendix 4C - quarterly
27/07/17PRICE SENSITIVE
SUD Strong Revenue Growth for SUDA Subsidiary
24/07/17PRICE SENSITIVE
SUD SUDA Enters Licence Agreement With Teva
05/07/17PRICE SENSITIVE
SUD Trading Halt
04/07/17PRICE SENSITIVE
SUD SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
20/06/17PRICE SENSITIVE
SUD SUDA Meeting For Zolpimist Into Europe
25/05/17PRICE SENSITIVE
SUD Placement, Interest Shares and Convertible Note Prospectus
24/04/17PRICE SENSITIVE
SUD Appendix 4C - quarterly
19/04/17PRICE SENSITIVE
SUD SUDA Completes $1.5m Capital Raising
07/04/17PRICE SENSITIVE
SUD Trading Halt
05/04/17PRICE SENSITIVE
SUD SUDA Submits Application For ArTiMist
03/04/17PRICE SENSITIVE
SUD SUDA Extends Maturity of Convertible Notes
03/04/17PRICE SENSITIVE
SUD SUDA Enters Feasibility Agreement With Pfizer
29/03/17PRICE SENSITIVE
SUD SUDA expands patent coverage for SUD-003 and SUD-004
03/03/17PRICE SENSITIVE
SUD SUDA Announces Strong Revenue For Westcoast
27/02/17PRICE SENSITIVE
SUD Half Yearly Report and Accounts
27/02/17PRICE SENSITIVE
SUD Reinstatement to official quotation
27/02/17PRICE SENSITIVE
SUD SUDA Update On Discussions with Berlin Pharma
27/02/17PRICE SENSITIVE
SUD Suspension from official quotation
27/01/17PRICE SENSITIVE
SUD Trading Halt
24/01/17PRICE SENSITIVE
SUD SUDA presents data on novel technology
17/11/16PRICE SENSITIVE
SUD SUDA Enters Licensing Agreement For ZolpiMist in China
09/11/16PRICE SENSITIVE
SUD Technology patent application-SUD.AX
02/11/16PRICE SENSITIVE
SUD Appendix 4C - quarterly-SUD.AX
31/10/16PRICE SENSITIVE
SUD Preliminary Final Report-SUD.AX
31/08/16PRICE SENSITIVE
SUD Appendix 4C - quarterly-SUD.AX
29/07/16PRICE SENSITIVE
SUD Update on HC Berlin Pharma-SUD.AX
03/06/16PRICE SENSITIVE
SUD Appendix 4C - quarterly-SUD.AX
29/04/16PRICE SENSITIVE
SUD Business development update-SUD.AX
19/04/16PRICE SENSITIVE
SUD SUDA granted Canadian Patent for SUD-002-SUD.AX
12/04/16PRICE SENSITIVE
SUD Half Yearly Report and Accounts (including Appendix 4D)
26/02/16PRICE SENSITIVE
SUD SUDA receives $0.7m R&D tax incentive refund
05/02/16PRICE SENSITIVE
SUD Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
SUD SUDA amends agreement with Amherst Pharmaceuticals
10/12/15PRICE SENSITIVE
SUD Response to Price Query Letter
07/12/15PRICE SENSITIVE
SUD Appendix 4C - quarterly
30/10/15PRICE SENSITIVE
SUD SUDA allowed first USA patent for SUD-003 and SUD-004
08/10/15PRICE SENSITIVE
SUD Preliminary Final Report
31/08/15PRICE SENSITIVE
SUD SUDA announces ArTiMist clinical publication
27/08/15PRICE SENSITIVE
SUD SUDA takes full control of ArTiMist
26/08/15PRICE SENSITIVE
SUD SUDA receives positive response from FDA regarding SUD-001
06/08/15PRICE SENSITIVE
SUD SUDA granted African patent for ArTiMist
31/07/15PRICE SENSITIVE
SUD Appendix 4C - quarterly
28/07/15PRICE SENSITIVE
SUD SUDA granted US patent for SUD-002 oral spray
27/07/15PRICE SENSITIVE
SUD SUDA progresses business development at BIO 2015
29/06/15PRICE SENSITIVE
SUD Appendix 4C - quarterly
30/04/15PRICE SENSITIVE
SUD SUDA announces ArTiMist peer-reviewed publications
24/04/15PRICE SENSITIVE
SUD Suda completes $5.3m capital raising
27/03/15PRICE SENSITIVE
SUD Trading Halt
26/03/15PRICE SENSITIVE
SUD Appendix 4D Half Year Ended 31 December 2014
27/02/15PRICE SENSITIVE
SUD Suda Granted First Patent For Sildenafil In Australia
30/01/15PRICE SENSITIVE
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.